BRPI0820557A2 - biomarcadores diagnósticos de diabetes - Google Patents

biomarcadores diagnósticos de diabetes

Info

Publication number
BRPI0820557A2
BRPI0820557A2 BRPI0820557A BRPI0820557A BRPI0820557A2 BR PI0820557 A2 BRPI0820557 A2 BR PI0820557A2 BR PI0820557 A BRPI0820557 A BR PI0820557A BR PI0820557 A BRPI0820557 A BR PI0820557A BR PI0820557 A2 BRPI0820557 A2 BR PI0820557A2
Authority
BR
Brazil
Prior art keywords
diabetes
diagnostic biomarkers
biomarkers
diagnostic
Prior art date
Application number
BRPI0820557A
Other languages
English (en)
Inventor
Derecho Carlo
U Lee Dong
X Yu Jack
F Palma John
W Backus John
Vener Tatiana
Zhang Yi
Wang Yixin
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40510430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820557(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of BRPI0820557A2 publication Critical patent/BRPI0820557A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/30—Microarray design
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Bioethics (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Software Systems (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
BRPI0820557A 2007-11-13 2008-11-13 biomarcadores diagnósticos de diabetes BRPI0820557A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98754007P 2007-11-13 2007-11-13
PCT/US2008/083424 WO2009064901A2 (en) 2007-11-13 2008-11-13 Diagnostic biomarkers of diabetes

Publications (1)

Publication Number Publication Date
BRPI0820557A2 true BRPI0820557A2 (pt) 2017-03-28

Family

ID=40510430

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820557A BRPI0820557A2 (pt) 2007-11-13 2008-11-13 biomarcadores diagnósticos de diabetes

Country Status (11)

Country Link
US (3) US20110275079A1 (pt)
EP (2) EP2215266B1 (pt)
JP (1) JP2011502537A (pt)
KR (1) KR101591738B1 (pt)
CN (1) CN101918589B (pt)
BR (1) BRPI0820557A2 (pt)
CA (1) CA2705195A1 (pt)
ES (1) ES2635429T3 (pt)
IL (1) IL205353A (pt)
MX (1) MX2010005281A (pt)
WO (1) WO2009064901A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009074988A1 (en) * 2007-12-10 2009-06-18 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods of diagnosing cancer
AU2010254259A1 (en) * 2009-05-29 2012-01-12 Emory University B cell signature associated with tolerance in transplant recipients
CN105808956A (zh) * 2009-10-19 2016-07-27 提拉诺斯公司 集成的健康数据采集和分析系统
KR20130028143A (ko) * 2010-07-08 2013-03-18 프라임 지노믹스, 인크. 복합 네트워크들에서의 전조직에 걸친 역학의 정화량화를 위한 시스템
CN104583403B (zh) * 2012-08-01 2017-11-17 深圳华大基因研究院 糖尿病生物标志物及其应用
WO2014019408A1 (en) * 2012-08-01 2014-02-06 Bgi Shenzhen Biomarkers for diabetes and usages thereof
BR112015008892A2 (pt) * 2012-10-18 2017-07-04 Fio Corp dispositivo, sistema, método e meio legível por computador para painel de teste de diagnóstico virtual
RU2016107170A (ru) * 2013-08-02 2017-09-07 Экоусенс Неинвазивная система для вычисления достоверной, стандартизованной и полной оценки человека или животного
EP2942356B1 (en) * 2014-05-05 2017-08-23 Medizinische Hochschule Hannover Mutation for type 1 diabetes mellitus and animal model
KR101658134B1 (ko) 2014-09-30 2016-09-21 연세대학교 산학협력단 PBMC 대사체 또는 Lp-PLA2 활성을 이용한 당뇨병에서의 진단 또는 스크리닝
KR101893244B1 (ko) 2015-05-22 2018-08-30 가천대학교 산학협력단 당뇨병에 대한 신규 바이오마커 및 그의 용도
WO2017032815A2 (en) * 2015-08-24 2017-03-02 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Biomarkers for cardiometabolic diseases
CN106609301B (zh) * 2015-10-26 2019-10-25 北京大学人民医院 一种辅助诊断1型糖尿病的试剂盒
CN107358047A (zh) * 2017-07-13 2017-11-17 刘峰 糖尿病患者评估及管理系统
CN110527717B (zh) * 2018-01-31 2023-08-18 完美（广东）日用品有限公司 用于2型糖尿病的生物标志物及其用途
CN108707661B (zh) * 2018-07-03 2021-03-23 张罗 Clc基因的特异性引物在制备用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒的应用
WO2020037174A1 (en) 2018-08-16 2020-02-20 The Johns Hopkins University Antibodies to human znt8
KR101977410B1 (ko) 2018-08-22 2019-05-10 주식회사 피플바이오 당뇨병에 대한 신규 바이오마커 및 그의 용도
CN109182508A (zh) * 2018-10-22 2019-01-11 北京华夏时代生物工程有限公司 Tcf7l2基因单核苷酸多态性的荧光原位杂交测序方法
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
CN114965753B (zh) * 2022-05-13 2026-03-31 重庆医科大学附属第一医院 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用
CN115851943A (zh) * 2022-11-17 2023-03-28 杭州艾迪康医学检验中心有限公司 一种检测top1基因表达量的试剂和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265869A1 (en) * 1999-01-06 2004-12-30 Chondrogene Limited Method for the detection of type II diabetes related gene transcripts in blood
US7442500B2 (en) * 2000-09-18 2008-10-28 Wisconsin Alumni Research Foundation Methods of diagnosing susceptibility to obesity
US20030036077A1 (en) * 2001-05-31 2003-02-20 Chronix Biomedical Methods for generating an mRNA expression profile from an ecellular mRNA containing blood sample and using the same to identify functional state markers
US20070054269A1 (en) * 2001-07-10 2007-03-08 Mendrick Donna L Molecular cardiotoxicology modeling
US20040146894A1 (en) * 2002-10-14 2004-07-29 Warrington Janet A. Methods of diagnosing and treating stress urinary incontinence
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050112584A1 (en) * 2003-11-20 2005-05-26 Cifuentes Francisco J. Methods for evaluating tissue pair combinations for use in nucleic acid array technology
EP1538219A1 (en) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Method to diagnose or screen for type 1 diabetes mellitus
WO2006060653A2 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7901885B2 (en) * 2006-05-09 2011-03-08 Dsm Ip Assets B.V. Genes and markers in type 2 diabetes and obesity
FR2910025A1 (fr) * 2006-12-19 2008-06-20 Biomerieux Sa Procede pour le diagnostic du diabete

Also Published As

Publication number Publication date
WO2009064901A3 (en) 2009-09-24
US20110275079A1 (en) 2011-11-10
IL205353A (en) 2015-02-26
EP2215266B1 (en) 2015-01-14
US20160138103A1 (en) 2016-05-19
CN101918589B (zh) 2016-08-17
KR20100093562A (ko) 2010-08-25
KR101591738B1 (ko) 2016-02-04
IL205353A0 (en) 2010-12-30
MX2010005281A (es) 2010-08-09
US20130217011A1 (en) 2013-08-22
WO2009064901A2 (en) 2009-05-22
CA2705195A1 (en) 2009-05-22
JP2011502537A (ja) 2011-01-27
CN101918589A (zh) 2010-12-15
EP2584050A1 (en) 2013-04-24
EP2215266A2 (en) 2010-08-11
EP2584050B1 (en) 2017-05-31
ES2635429T3 (es) 2017-10-03

Similar Documents

Publication Publication Date Title
IL205353A0 (en) Diagnostic biomarkers of diabetes
BRPI0919058A2 (pt) indicador biológico independente
EP2195114A4 (en) INSTRUMENTED PIPETTLE TIP
EP2263082A4 (en) ANALYSIS OF BLOOD VISCOSITY
FI20096188A0 (fi) Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle
PL2349143T3 (pl) Instrument wprowadzający
EP2155058A4 (en) INDICATOR
EP2129285A4 (en) Analyte sensor
BRPI0920069A2 (pt) biomarcadores
EP2429400A4 (en) QUANTITATIVE ENDOSCOPY
BRPI0820928A2 (pt) Fabricação de elementos com baixa fricção
EP2303099A4 (en) INTEGRATED ENDOSCOPIC MULTIFUNCTIONAL INSTRUMENT
EP2311518A4 (en) MEDICAL INSTRUMENT
EP2258421A4 (en) MEDICAL INSTRUMENT
EP2089722A4 (en) BIOMARKERS
EP2265642A4 (en) BIOMARKERS
ES1069963Y (es) Ensamblaje de corredera
EP2284538A4 (en) Biosensor
EP2198781A4 (en) Puncture
EP2008587A4 (en) Lancet assembly
EP2425226A4 (en) PIPETTE DEVICE
EP2280284A4 (en) Biosensor
BRPI0914098A2 (pt) biosensor
BRPI0813681A2 (pt) Detecção de coproantígeno de nematelminto
EP2110789A4 (en) PAPER MONEY PROCESSOR

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements